Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aprindine is a long-acting Class Ib antiarrhythmic agent used primarily for the treatment of ventricular arrhythmias and, to a lesser extent, supraventricular arrhythmias. It acts by directly interfering with depolarization of the cardiac cell membrane through blockade of fast inward sodium channels, thereby reducing the rate of rise of the action potential and shortening repolarization. This elevates the fibrillation threshold and shortens the QT interval. Aprindine is effective when administered orally or intravenously and may be particularly useful in conditions such as Wolff-Parkinson-White syndrome. The drug is not approved in the United States but is available in some European countries and Japan[1][3][4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aprindine.